Company · LCTX
Lineage Cell Therapeutics, Inc.
Nasdaq's symbol directory lists LCTX on NYSE American as “Lineage Cell Therapeutics, Inc. Common Stock”.
In the 12 months to Nov 19, 2026: insiders bought on 3 occasions ($74K); 1 company report (Form 8-K, since May 26, 2026).
Insider trades · SEC Form 4
Those inside the hall
Open-market purchases and sales only. Legs one person filed for one day are combined.
Who traded
- Brian M. Culley, President and CEO bought $37K
- Deborah J. Andrews bought $20K
- Jill A. Howe, Chief Financial Officer bought $17K
Every trade (3)
- BUYBrian M. Culley, President and CEO bought $37K
- BUYDeborah J. Andrews bought $20K
- BUYJill A. Howe, Chief Financial Officer bought $17K
Company reports · SEC Form 8-K
In its own words
Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.
- Entry into a material definitive agreement; Completion of acquisition or disposition of assets; Results of operations and financial condition; Unregistered sales of equity securities; Regulation FD disclosure Nov 12, 2026
Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.